Drugs in Medical Technology

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity

EMERYVILLE, Calif., July 17 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One. ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today that the FDA's Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with m...

Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study

- 12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea - NAPA, Calif., May 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that targ...

Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009

NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, ha...

New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation

DALLAS, March 5 /PRNewswire/ -- A study published by Deborah S. Sarnoff, M.D. et al in the February issue of the Journal of Drugs in Dermatology explores the new generation of carbon dioxide (CO2) laser skin resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes a...

Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease

Research Uncovers New Link Between Inflammation & Alzheimer's Disease SARASOTA, Fla., Dec. 16 /PRNewswire/ -- The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer's disease and have identified a potential target for de...

Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome

REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) announced today that the Anti-infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous iclaprim, an antibiotic currently in development ...

Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207

Study results to be presented at 2008 ICAAC/IDSA Joint Meeting ROCKVILLE, Md., Oct. 28 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential, announces the successful demonstration of ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology. MLN4924 data build on the growing body of evidence ...

VAI Finding Could Lead to New Drugs for Anxiety, Depression

Researchers determine molecular structure of promising drug target using new method GRAND RAPIDS, Mich., Oct. 15 /PRNewswire/ -- Researchers in the Laboratory of Structural Sciences at Van Andel Institute (VAI) have determined how the hormone corticotrophin releas...

China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials

HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it s...

Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation

DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals ( http://www.addrenex.com ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months. The fast-paced timeline they have set for ...

Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder

Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare...

Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins

Lead Candidate Set for Phase II Clinicals LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today that it has been granted an exclusive, worldwide license from Duke University and Johns H...

Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist

NEW YORK, April 8, 2008 /PRNewswire/ -- If you're suffering from back pain and unable to find relief, it may be because the real cause of your pain -- weak, stressed and damaged muscles, not your spine -- has never been recognized or treated, says Norman Marcus, M.D., one of the nation's leadi...

Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis

Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and adv...

Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote

GAITHERSBURG, Md., March 13 /PRNewswire/ -- Ortho Biotech is concerned by the Advisory Committee's recommendations to restrict access to erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA) in patients with metastatic breast and head and neck cancer, and patients trea...

NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference

NEW YORK, Feb. 22 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the GTCBio 5th Annual Cancer Drugs Research & Development Conference taking place in Phoenix, Arizona. The company presented data on NXD30001, one of several novel, radicicol-base...

Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future

BETHESDA, Md., Feb. 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a comprehensive review article entitled, ...

Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood

AVALIDE demonstrated powerful mean blood pressure reductions of 30.8 mm Hg systolic blood pressure (SBP) and 24.0 mm Hg diastolic blood pressure (DBP) at five weeks and 21.1/19.3 mm Hg (SBP/DBP) for irbesartan alone in a study of patients with severe hypertension AVALIDE also de...

Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism

BOSTON, Oct. 5 /PRNewswire/ -- Surface Logix, Inc. today announced the presentation of positive safety and efficacy data from its innovative Phase 1 repeat-dose clinical trial of its investigational drug candidate SLx-4090, a first-in-class enterocyte-specific microsomal triglyceride transfer ...

Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference

Lead Compound Produces Significant LDL-Cholesterol Reduction and Weight Loss When Combined with Zetia(R) in Hypercholesterolemic Patients BRIDGEWATER, N.J., Oct. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular an...

Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications...

Dry Mouth Linked to Prescription and Over the Counter Drugs

BALTIMORE, July 9 /PRNewswire-USNewswire/ -- Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by...

Key Protein May Lead to Faster Acting Anti-Depression Drugs

NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University , Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal o...

The Children's Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohn's Disease Drugs

- Broadens Power of Current Genetic Discovery Techniques - PHILADELPHIA, Feb. 26 /PRNewswire-USNewswire/ -- Discovering the different genes that contribute to a complex disease is like searching in the proverbial haystack for an unknown number of needles -- some much smaller than others, ...

Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs

Study results pending publication in July print edition of Clinical Chemistry, available on Web INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) confirms the potent...

Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs

- Results Presented at Endocrine Society's 90th Annual Meeting - SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results on the role of estrogen regulatory elements important in developing drugs for breast cancer and ost...

Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs

ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced today the completion of a Service Agreement...

First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs

HWI Scientist Dr. Dan Gewirth's Groundbreaking Research Makes Cover of Molecular Cell BUFFALO, N.Y., Oct. 19 /PRNewswire/ -- Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated ...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

- Publication in Leading Peer-Reviewed Journal Represents Further Scientific Validation of the Potential Utility of Modigene's CTP Technology - VIENNA, Va., Sept. 24 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today reported that rese...

New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs

MELBOURNE, Australia, Aug. 28 /PRNewswire/ -- Cancer Therapeutics CRC Pty Ltd (CTx) has commenced operations as one of the largest public/private partnerships of its type in the world. Underpinned by AUD$148 million in funding over seven years, including AUD$37.6 million from the Australian C...

Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells

NEW YORK--(BUSINESS WIRE)--Apr 16, 2007 - Arsenic, a naturally occurring element, has been used in therapeutic compounds for over 2,000 years, and even now remains a venerable constituent of the traditional Chinese pharmacopeia. Today, due in measure to the efforts of investigators supported by gr...

NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 7, 2007 - NanoViricides, Inc. (Pink Sheets: NNVC) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology...

Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment

NEW YORK, June 13, 2007--Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition. The findings are reported in a New Drug Class study published early Online and in an upcoming edition of The Lancet. RA is the most common ...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c60415) has announced the addition of Looking at Chiral Technologies to their offering. The advancements in molecular research and continued untiring efforts of the research industry to...

New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV

Phase III clinical trial provides hope that HIV patients can live longer lives PASADENA, Calif., July 05, 2007 /PRNewswire/ -- A new investigational drug used in combination with a second newer agent has proven to be effective in fighting drug-resistant HIV, according to a Lancet article to be pub...

Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse

In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require l...

Global Rabies Treatment May be Possible with NanoViricides Drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 14, 2007 - NanoViricides, Inc. (Pink Sheets: NNVC) discussed today the results of recent animal studies against rabies that were presented along with the successful BSL3 in vitro studies against a Clade 2 H5N1 virus at the 23rd Annual Symposium of the Pan Ame...